A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

Fibrin-specific plasminogen activator TNKase (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years, joining Roche/Genentech's Activase (alteplase), which is the only ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...